CA2434995A1 - Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac - Google Patents

Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac Download PDF

Info

Publication number
CA2434995A1
CA2434995A1 CA002434995A CA2434995A CA2434995A1 CA 2434995 A1 CA2434995 A1 CA 2434995A1 CA 002434995 A CA002434995 A CA 002434995A CA 2434995 A CA2434995 A CA 2434995A CA 2434995 A1 CA2434995 A1 CA 2434995A1
Authority
CA
Canada
Prior art keywords
reovirus
neoplasm
administered
cancer
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002434995A
Other languages
English (en)
Inventor
Patrick W. K. Lee
Kara L. Norman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002434995A priority Critical patent/CA2434995A1/fr
Publication of CA2434995A1 publication Critical patent/CA2434995A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002434995A 2003-07-07 2003-07-07 Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac Abandoned CA2434995A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002434995A CA2434995A1 (fr) 2003-07-07 2003-07-07 Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002434995A CA2434995A1 (fr) 2003-07-07 2003-07-07 Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac

Publications (1)

Publication Number Publication Date
CA2434995A1 true CA2434995A1 (fr) 2005-01-07

Family

ID=33569526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002434995A Abandoned CA2434995A1 (fr) 2003-07-07 2003-07-07 Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac

Country Status (1)

Country Link
CA (1) CA2434995A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations

Similar Documents

Publication Publication Date Title
AU782020B2 (en) Viruses for the treatment of cellular proliferative disorders
AU776401B2 (en) Reovirus for the treatment of cellular proliferative disorders
EP2189162B1 (fr) Méthode pour le traitement des troubles de la prolifération cellulaire
AU2002212022A2 (en) Methods for the treatment of cellular proliferative disorders
AU2002212022A1 (en) Methods for the treatment of cellular proliferative disorders
US7163678B2 (en) Reovirus for the treatment of ral-mediated cellular proliferative disorders
US20050019308A1 (en) Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac
EP3068411B1 (fr) Virus oncolytiques et schémas posologiques de traitement du cancer renforcés
CA2434995A1 (fr) Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac
CA2411397C (fr) Reovirus pour le traitement de troubles de la proliferation cellulaire induits par ral
US20020187465A1 (en) Viruses for the treatment of cellular proliferative disorders
COFFEY et al. Sommaire du brevet 2388807

Legal Events

Date Code Title Description
FZDE Dead